Total Valuation
ONO Pharmaceutical Co has a market cap or net worth of $126.32B. The enterprise value is $960.85B.
Market Cap$126.32B
Enterprise Value$960.85B
Share Statistics
ONO Pharmaceutical Co has 498,692,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding498,692,800
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
ONO Pharmaceutical Co’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 5.65%.
Return on Equity (ROE)0.06
Return on Assets (ROA)0.05
Return on Invested Capital (ROIC)5.65%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee115.76M
Profits Per Employee11.90M
Employee Count4,206
Asset Turnover0.46
Inventory Turnover2.02
Valuation Ratios
The current PE Ratio of ONO Pharmaceutical Co is 14.2. ONO Pharmaceutical Co’s PEG ratio is 0.43.
PE Ratio14.2
PS Ratio2.29
PB Ratio1.39
Price to FCF9.02
Price to Operating Cash Flow―
PEG Ratio0.43
Income Statement
In the last 12 months, ONO Pharmaceutical Co had revenue of 486.87B and earned 50.05B in profits. Earnings per share was 106.55.
Revenue486.87B
Gross Profit335.47B
Operating Income63.38B
Pretax Income59.33B
Net Income50.05B
EBITDA87.86B
Earnings Per Share (EPS)106.55
Cash Flow
In the last 12 months, operating cash flow was 125.64B and capital expenditures -6.37B, giving a free cash flow of 119.27B billion.
Operating Cash Flow125.64B
Free Cash Flow119.27B
Free Cash Flow per Share239.16
Dividends & Yields
ONO Pharmaceutical Co pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.21
52-Week Price Change34.06%
50-Day Moving Average281.26
200-Day Moving Average271.82
Relative Strength Index (RSI)99.97
Average Volume (3m)0.00
Important Dates
ONO Pharmaceutical Co upcoming earnings date is Feb 1, 2027, TBA (Confirmed).
Last Earnings DateOct 29, 2026
Next Earnings DateFeb 1, 2027
Ex-Dividend Date―
Financial Position
ONO Pharmaceutical Co as a current ratio of 3.07, with Debt / Equity ratio of ―
Current Ratio3.07
Quick Ratio2.56
Debt to Market Cap0.18
Net Debt to EBITDA-0.66
Interest Coverage Ratio38.77
Taxes
In the past 12 months, ONO Pharmaceutical Co has paid 9.16B in taxes.
Income Tax9.16B
Effective Tax Rate0.15
Enterprise Valuation
ONO Pharmaceutical Co EV to EBITDA ratio is 7.91, with an EV/FCF ratio of 9.02.
EV to Sales1.43
EV to EBITDA7.91
EV to Free Cash Flow9.02
EV to Operating Cash Flow8.43
Balance Sheet
ONO Pharmaceutical Co has $189.27B in cash and marketable securities with $109.99B in debt, giving a net cash position of $64.84B billion.
Cash & Marketable Securities$189.27B
Total Debt$109.99B
Net Cash$64.84B
Net Cash Per Share$130.02
Tangible Book Value Per Share$930.34
Margins
Gross margin is ―, with operating margin of 13.02%, and net profit margin of 10.28%.
Gross Margin―
Operating Margin13.02%
Pretax Margin12.19%
Net Profit Margin10.28%
EBITDA Margin18.05%
EBIT Margin12.52%
Analyst Forecast
The average price target for ONO Pharmaceutical Co is $263.87, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
Price Target$263.87
Price Target Upside-5.76% Downside
Analyst ConsensusModerate Sell
Analyst Count1
Revenue Growth Forecast-16.79%
EPS Growth Forecast33.12%